Patients with cancer have an increased risk of venous thromboembolism (VTE) compared with non-cancer patients.1 In these patients, the risk of VTE is variable and seems to be related to several factors including cancer site and extension, anti-cancer treatment and several intrinsic patient characteristics.2,3 Low-molecular-weight heparin (LMWH) has been for many years the treatment of choice for cancer-related VTE. The European Society of Cardiology (ESC) guidelines published in 2019 opened to the use of direct oral anticoagulants (DOACs) for treatment of cancerrelated VTE.4
Risk scores for death in patients with cancer-related venous thromboembolism. still a long road ahead / Pastori, D.; Agnelli, G.. - In: THROMBOSIS AND HAEMOSTASIS. - ISSN 0340-6245. - 121:6(2021), pp. 700-702. [10.1055/s-0041-1727244]
Risk scores for death in patients with cancer-related venous thromboembolism. still a long road ahead
Pastori D.
;
2021
Abstract
Patients with cancer have an increased risk of venous thromboembolism (VTE) compared with non-cancer patients.1 In these patients, the risk of VTE is variable and seems to be related to several factors including cancer site and extension, anti-cancer treatment and several intrinsic patient characteristics.2,3 Low-molecular-weight heparin (LMWH) has been for many years the treatment of choice for cancer-related VTE. The European Society of Cardiology (ESC) guidelines published in 2019 opened to the use of direct oral anticoagulants (DOACs) for treatment of cancerrelated VTE.4| File | Dimensione | Formato | |
|---|---|---|---|
|
Pastori_Risk_2021.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
112.16 kB
Formato
Adobe PDF
|
112.16 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
